Pasteurized Akkermansia muciniphila in obesity and metabolic syndrome: mechanisms of action and clinical potential
https://doi.org/10.20996/1819-6446-2026-3365
EDN: UZMVFO
Abstract
The aim of this review is to systematize current data on the mechanisms of action of pasteurized Akkermansia muciniphila in obesity and metabolic syndrome and to evaluate its clinical potential. Obesity and metabolic syndrome are leading risk factors for cardiovascular disease. In recent years, compelling evidence has accumulated on the important role of intestinal microbiota dysbiosis in the pathogenesis of these conditions, opening up prospects for the development of new therapeutic strategies aimed at its correction. Pasteurized A. muciniphila is of interest as a potentially promising postbiotic capable of preserving the effects of live bacteria while simultaneously enhancing its safety profile. Pasteurized A. muciniphila has been shown to exert a multicomponent effect, including reduction of intestinal barrier permeability, metabolic endotoxemia, and chronic low-grade inflammation, modulation of intestinal glucose transport, interaction with the gut-brain axis, and regulation of energy metabolism. Currently, efficacy data remain limited and are based primarily on preclinical studies. A. muciniphila has been shown to reduce body weight and fat mass, improve glycemic control, increase insulin sensitivity, and reduce inflammatory and fibrotic changes in the liver and adipose tissue. However, there remains a need to standardize postbiotic formulations, including pasteurization and dosing regimens, and to conduct large, long-term randomized trials to determine clinical efficacy and safety.
References
1. Sasidharan Pillai S, Gagnon CA, Foster C, Ashraf AP. Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes. J Clin Endocrinol Metab. 2024 Oct 15;109(11):2709–19. doi:10.1210/clinem/dgae499
2. Leonov G, Livantsova E, Varaeva Y, Starodubova A. Probiotics and Prebiotics in Post-Myocardial Infarction Rehabilitation: Mechanisms, Benefits, and Future Directions. Curr Nutr Rep. 2025 Jun 28;14(1):88. doi:10.1007/s13668-025-00679-4
3. Romantsova TI, Sych YuP. Immunometabolism and metaflammation in obesity. Ozhirenie i Metabolizm. 2019;16(4):3-17 (In Russ.) [Романцова Т.И., Сыч Ю.П. Иммунометаболизм и метавоспаление при ожирении. Ожирение и метаболизм. 2019;16(4):3-17].
4. Vetrani C, Di Nisio A, Paschou SA, Barrea L, Muscogiuri G, Graziadio C, et al. From Gut Microbiota through Low-Grade Inflammation to Obesity: Key Players and Potential Targets. Nutrients. 2022 May 18;14(10):2103. doi:10.3390/nu14102103
5. Hassan NE, El-Masry SA, El Shebini SM, Ahmed NH, Mohamed T F, Mostafa MI, et al. Gut dysbiosis is linked to metabolic syndrome in obese Egyptian women: potential treatment by probiotics and high fiber diets regimen. Sci Rep. 2024 Mar 5;14(1):5464. doi:10.1038/s41598-024-54285-5
6. Kang C, Wang B, Kaliannan K, Wang X, Lang H, Hui S, et al. Gut Microbiota Mediates the Protective Effects of Dietary Capsaicin against Chronic Low-Grade Inflammation and Associated Obesity Induced by High-Fat Diet. mBio. 2017 May 23;8(3):10.1128/mbio.00470-17. doi:10.1128/mbio.00470-17
7. Koumpouli D, Koumpouli V, Koutelidakis AE. Functional Foods, Gut Microbiome and Association with Obesity and Metabolic Syndrome: A Literature Review. Appl Sci. 2024 Jun 26;14(13). doi:10.3390/app14135578
8. Kim YT, Mills DA. Exploring the gut microbiome: probiotics, prebiotics, synbiotics, and postbiotics as key players in human health and disease improvement. Food Sci Biotechnol. 2024 Jun 27;33(9):2065–80. doi:10.1007/s10068-024-01620-1
9. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506–14. doi:10.1038/nrgastro.2014.66
10. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016 Mar;65(3):426–36. doi:10.1136/gutjnl-2014-308778
11. Yoon HS, Cho CH, Yun MS, Jang SJ, You HJ, Kim J hyeong, et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat Microbiol. 2021 May;6(5):563–73. doi:10.1038/s41564-021-00880-5
12. Zhang Y, Liu R, Chen Y, Cao Z, Liu C, Bao R, et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut. Cell Metab. 2025 Mar 4;37(3):592-605.e6. doi:10.1016/j.cmet.2024.12.010
13. Wegh CAM, Geerlings SY, Knol J, Roeselers G, Belzer C. Postbiotics and Their Potential Applications in Early Life Nutrition and Beyond. Int J Mol Sci. 2019 Sep 20;20(19):4673. doi:10.3390/ijms20194673
14. Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):649–67. doi:10.1038/s41575-021-00440-6
15. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004 Sep;54(Pt 5):1469–76. doi:10.1099/ijs.0.02873-0
16. Chiantera V, Laganà AS, Basciani S, Nordio M, Bizzarri M. A Critical Perspective on the Supplementation of Akkermansia muciniphila: Benefits and Harms. Life. 2023 May 24;13(6):1247. doi:10.3390/life13061247
17. Mierlan OL, Busila C, Amaritei O, Elena D, Raileanu CR, Maftei NM, et al. Akkermansia muciniphila in Metabolic Disease: Far from Perfect. Int J Mol Sci. 2025 Jan;26(23):11602. doi:10.3390/ijms262311602
18. Trastoy B, Naegeli A, Anso I, Sjögren J, Guerin ME. Structural basis of mammalian mucin processing by the human gut O-glycopeptidase OgpA from Akkermansia muciniphila. Nat Commun. 2020 Sep 24;11(1):4844. doi:10.1038/s41467-020-18696-y
19. Mo C, Lou X, Xue J, Shi Z, Zhao Y, Wang F, et al. The influence of Akkermansia muciniphila on intestinal barrier function. Gut Pathog. 2024 Aug 3;16(1):41. doi:10.1186/s13099-024-00635-7
20. Martin-Gallausiaux C, Garcia-Weber D, Lashermes A, Larraufie P, Marinelli L, Teixeira V, et al. Akkermansia muciniphila upregulates genes involved in maintaining the intestinal barrier function via ADP-heptose-dependent activation of the ALPK1/TIFA pathway. Gut Microbes. 2022;14(1):2110639. doi:10.1080/19490976.2022.2110639
21. Wade H, Pan K, Duan Q, Kaluzny S, Pandey E, Fatumoju L, et al. Akkermansia muciniphila and its membrane protein ameliorates intestinal inflammatory stress and promotes epithelial wound healing via CREBH and miR-143/145. J Biomed Sci. 2023 Jun 7;30(1):38. doi:10.1186/s12929-023-00935-1
22. Costa RL, Moreira J, Lorenzo A, Lamas CC. Infectious complications following probiotic ingestion: a potentially underestimated problem? A systematic review of reports and case series. BMC Complement Altern Med. 2018 Dec 12;18:329. doi:10.1186/s12906-018-2394-3
23. D’Agostin M, Squillaci D, Lazzerini M, Barbi E, Wijers L, Da Lozzo P. Invasive Infections Associated with the Use of Probiotics in Children: A Systematic Review. Children. 2021 Oct 16;8(10):924. doi:10.3390/children8100924
24. Mg B, Hc van S, E B, Ma B, H van G, Hm T, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2008 Feb 23;371(9613). doi:10.1016/S0140-6736(08)60207-X
25. Choi Y, Bose S, Seo J, Shin JH, Lee D, Kim Y, et al. Effects of Live and Pasteurized Forms of Akkermansia from the Human Gut on Obesity and Metabolic Dysregulation. Microorganisms. 2021 Sep 27;9(10):2039. doi:10.3390/microorganisms9102039
26. Karbowiak M, Gałek M, Szydłowska A, Zielińska D. The Influence of the Degree of Thermal Inactivation of Probiotic Lactic Acid Bacteria and Their Postbiotics on Aggregation and Adhesion Inhibition of Selected Pathogens. Pathogens. 2022 Oct 29;11(11):1260. doi:10.3390/pathogens11111260
27. Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch‐Ernst KI, Maciuk A, et al. Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J. 2021 Sep 1;19(9):e06780. doi:10.2903/j.efsa.2021.6780
28. Piqué N, Berlanga M, Miñana-Galbis D. Health Benefits of Heat-Killed (Tyndallized) Probiotics: An Overview. Int J Mol Sci. 2019 May 23;20(10):2534. doi:10.3390/ijms20102534
29. Abraham L, Raise A, Beney L, Lapaquette P, Rieu A. Membrane vesicles produced by next-generation probiotics from the gut as innovative tools for human health. Gut Microbes. 2025 Dec 31;17(1):2552344. doi:10.1080/19490976.2025.2552344
30. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017 Jan;23(1):107–13. doi:10.1038/nm.4236
31. Wachsmuth HR, Weninger SN, Duca FA. Role of the gut–brain axis in energy and glucose metabolism. Exp Mol Med. 2022 Apr 26;54(4):377–92. doi:10.1038/s12276-021-00677-w
32. Abot A, Brochot A, Pomié N, Astre G, Druart C, de Vos WM, et al. Pasteurized Akkermansia muciniphila improves glucose metabolism is linked with increased hypothalamic nitric oxide release. Heliyon. 2023 Jul 13;9(7):e18196. doi:10.1016/j.heliyon.2023.e18196
33. Depommier C, Van Hul M, Everard A, Delzenne NM, De Vos WM, Cani PD. Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice. Gut Microbes. 2020 Sep 2;11(5):1231–45. doi:10.1080/19490976.2020.1737307
34. Wu Z, Xiao Y, Zhou F, Chen J, Chen X, Hou A, et al. Pasteurized Akkermansia muciniphila Reduces Fat Accumulation via nhr-49-Mediated Nuclear Hormone Signaling Pathway in Caenorhabditis elegans. Molecules. 2022 Sep 20;27(19):6159. doi:10.3390/molecules27196159
35. Keshavarz Azizi Raftar S, Ashrafian F, Yadegar A, Lari A, Moradi HR, Shahriary A, et al. The Protective Effects of Live and Pasteurized Akkermansia muciniphila and Its Extracellular Vesicles against HFD/CCl4-Induced Liver Injury. Microbiol Spectr. 2021 Oct 31;9(2):e0048421. doi:10.1128/Spectrum.00484-21
36. Zhang M, Wang Y, Gan Y. The potential role of Akkermansia muciniphila in liver health. Future Microbiol. 19(12):1081–96. doi:10.2217/fmb-2023-0220
37. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019 Jul;25(7):1096–103. doi:10.1038/s41591-019-0495-2
38. Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe-/- Mice. Circulation. 2016 Jun 14;133(24):2434–46. doi:10.1161/CIRCULATIONAHA.115.019645
39. Kim JY, Kim CW, Oh SY, Jang S, Yetunde OZ, Kim BA, et al. Akkermansia muciniphila extracellular vesicles have a protective effect against hypertension. Hypertens Res. 2024 Jun;47(6):1642–53. doi:10.1038/s41440-024-01627-5
40. Zhang Y, Liu R, Chen Y, Cao Z, Liu C, Bao R, et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut. Cell Metab. 2025 Mar 4;37(3):592-605.e6. doi:10.1016/j.cmet.2024.12.010
41. Roshanravan N, Mahdavi R, Alizadeh E, Ghavami A, Rahbar Saadat Y, Mesri Alamdari N, et al. The effects of sodium butyrate and inulin supplementation on angiotensin signaling pathway via promotion of Akkermansia muciniphila abundance in type 2 diabetes; A randomized, double-blind, placebo-controlled trial. J Cardiovasc Thorac Res. 2017;9(4):183–90. doi:10.15171/jcvtr.2017.32
42. Druart C, Plovier H, Van Hul M, Brient A, Phipps KR, de Vos WM, et al. Toxicological safety evaluation of pasteurized Akkermansia muciniphila. J Appl Toxicol JAT. 2021 Feb;41(2):276–90. doi:10.1002/jat.4044
43. Niu H, Zhou M, Zogona D, Xing Z, Wu T, Chen R, et al. Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases. Front Immunol. 2024;15:1370658. doi:10.3389/fimmu.2024.1370658
Review
For citations:
Leonov G.E., Starodubova A.V. Pasteurized Akkermansia muciniphila in obesity and metabolic syndrome: mechanisms of action and clinical potential. Rational Pharmacotherapy in Cardiology. (In Russ.) https://doi.org/10.20996/1819-6446-2026-3365. EDN: UZMVFO
Views:
30
JATS XML
.jpg)
Email this article 